COGNITE
5.10.2021 13:02:10 CEST | Business Wire | Press release
In the midst of the largest industrial revolution, Cognite , a leader in industrial digitalization, announced the release of The Definitive Guide To Industrial DataOps . A first for the industry, the book defines and explains the emerging discipline of Industrial DataOps in language crafted for both business and IT professionals, while addressing the urgency driven by accelerating, data-driven shifts that modern organizations now navigate. The insights and industry expertise captured in the book also offer organizations practical advice on successful Industrial DataOps adoption and scaling. A request for proposal (RFP) guide, and a self-assessment to evaluate organizational readiness and map out challenges, round out the actionable insights and tools covered in the book.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005582/en/
Industrial DataOps is already becoming a driving force in industrial transformations, helping accelerate digital maturity, enabling data teams to deliver more digital products, and realizing more operational value at scale. In a 2020 survey of global companies, McKinsey found organizations that embedded DataOps could see the volume of new features increase by 50 percent because data automation enables quicker development iterations.
“Data trust comes from connecting the dots between desired outcomes and relevant use-case-oriented data products,” says Forrester VP, Principal Analyst Michele Goetz. “An Industrial DataOps platform brings context to data conditions and ensures business impacting data anomalies are caught early to mitigate costly issues. A DataOps platform also ensures data complies with data models and output standards to drive results from event-based intelligence inside processes.”
‘The Definitive Guide to Industrial DataOps’ was written to de-hype industrial digitalization and to help make sense of how Industrial DataOps allows organizations to manage complex data. The book’s structure reflects the journey that industrial companies will take as they evaluate, adopt, and scale Industrial DataOps across their organizations. The early chapters cover the urgency of Industrial DataOps and get readers to take stock of their industrial organizations’ digital maturity. The core chapters address the discipline itself, its key principles, and how to best extract value from data, while the final chapters define the way forward: scaling Industrial DataOps and putting it into practice.
“Industrial DataOps is a crucial and necessary tool to make digital transformation possible in asset-intensive industries,” says John Markus Lervik, CEO and co-founder of Cognite. “It illustrates how to connect data from the IT and OT source to the data consumer with contextual tips that will empower organizations of all sizes to use it, innovate off of it, and reshape operations for efficiency, profitability, and sustainability. It is the strongest driver of change that will propel the industry forward, and this book will help companies as they navigate their way and capture immediate value at scale.”
“To make the promise of Industrial DataOps a reality for enterprises, ´The Definitive Guide to Industrial DataOps´ serves as a critical manual to not only understand this novel software category, but as well how it accelerates innovation and reduces time-to-value at each stage of a digital operations transformation,” says Pascal Brosset, Industry X Production & Operations Lead at Accenture.
The full book is available for download for free: The Definitive Guide To Industrial DataOps
About Cognite
Cognite is a global industrial SaaS company that was established with one clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-intensive industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion™, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter @CogniteData or LinkedIn: https://www.linkedin.com/company/cognitedata .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom